CTI Corporate Presentation

November 2010

James A. Bianco, M.D.

Chief Executive Officer

Exhibit 99.1

2

Forward Looking Statement

This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation

Reform Act of 1995. The forward-looking statements contained in this presentation include statements about future financial and operating

results, and risks and uncertainties that could affect CTI’s products under development. These statements are based on management’s current

expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those

described in the forward-looking statements. These statements are not guarantees of future performance, involve certain risks, uncertainties

and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore,

actual outcomes and results may differ materially from what is expressed herein. In any forward-looking statement in which CTI expresses an

expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but

there can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. 

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements:

risks associated with preclinical, clinical and sales and marketing developments in the biopharmaceutical industry in general and in particular

including, without limitation, the potential failure of Opaxio™ to prove safe and effective for treatment of non-small cell lung and ovarian

cancers, the potential failure of Pixuvri™ (pixantrone dimaleate) to prove safe and effective (including complete and overall response rates)

for treatment of non-Hodgkin’s lymphoma as determined by the U.S. Food and Drug Administration (the “FDA”) and/or the European Medicine

Agency (the “EMEA”), that CTI’s appeal to the FDA may not be successful, that the FDA’s decision regarding CTI’s appeal may not be made

within 30 days of submission, that the FDA may not accept CTI's Special Protocol Assessment (“SPA”) and/or the proposed design for the

protocol of CTI's clinical trial and/or may request additional clinical trials, that the FDA may revise or may not accept the proposed endpoints fo

the additional clinical trial, that if CTI conducts an additional clinical trial, it may not demonstrate the safety and effectiveness of Pixuvri™, that

CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, including whether or not the majority of the patients

will be enrolled in the U.S., that CTI may not initiate the new PIX306 trial in 2010 or obtain data by the end of 2011, that the EMEA may not

approve the MAA, that CTI may not obtain interim survival results for the Phase III GOG212 trial in 2011, that CTI may not achieve expected

key milestones in the next twelve months or at all, that CTI may not be able to retire its 2011 debt, that CTI’s expected financing of up to $75

million over the next two years may not occur or the terms of such financing may change, CTI’s ability to continue to raise capital as needed to

fund its operations, that CTI may not be able to reduce its burn rate as expected, determinations by regulatory, patent and administrative

governmental authorities, competitive factors, technological developments, costs of developing, producing and selling CTI’s products under

development; and other economic, business, competitive, and/or regulatory factors affecting CTI’s business generally, including those set forth

in CTI’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for its most recent fiscal year and

its most recent Quarterly Report on Form 10-Q, especially in the “Factors Affecting Our Operating Results” and “Management’s Discussion and

Analysis of Financial Condition and Results of Operations” sections, and its Current Reports on Form 8-K. Except as may be required by law,

CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

3

Investment considerations

Attractive late-stage product portfolio

•

Potential approval and EU launch in 2011

Products targeting large market opportunities

•

Lymphoma –

25,000 patients/yr

•

Ovarian Cancer-

30,000 patients/yr

•

Breast Cancer –

100,000 patients/yr

History of important & meaningful advances in cancer

therapy with socially responsible pricing

Cleaned-up balance sheet and liquid stock, key

near-term catalysts

Management team with extensive oncology development

and commercial experience

4

Development Update

Advancing Portfolio Toward Market

•

Pixuvri

™

-

EMA acceptance of Marketing Authorization Application

•

Potential approval in Q4-2011

-

Appealing FDA decision on New Drug Application

•

Decision expected within 30 days from submission

-

Preparing initiation of PIX306 Phase III trial

•

Targeting preliminary data by year-end 2011

•

Opaxio

™

-

Phase III GOG212 trial in ovarian cancer trial

•

Potential interim survival results 2011

-

Exciting potential “accelerated”

application potential in GBM

5

Corporate Update: Roll-up Strategy

Successful acquisition strategy

•

Two product approvals

-

Trisenox®

-

acquired 2000

•

NDA and launch 2000

•

MAA and launch 2001

•

Peak sales $22mm -

sold to Cephalon

$70mm

-

Zevalin®

-

•

sBLA

2007

•

Sales $11mm -sold to Spectrum $31.5mm

6

Corporate Update: Roll-up Strategy

Excellent track record uncovering viable products

•

Aloxi

–

2008 WW sales $400mm

-

Helsin

offered opportunity for Phase III program to CTI

•

$30mm upfront, $65mm success fees

•

Couldn’t support acquisition internally –

MGI pharma

acquired rights

•

Eisai acquired MGI for $3 billion

-

Advanced

acquisition

proceedings

of

Sangstat

($150mm

purchase

price)

when product sales ~$35mm

•

Genzyme

acquired Sangstat

for $1 billion

•

Romidepsin

-

Pre-emptive (prior to ODAC)  purchase price $250mm ($100mm upfront)

-

Advanced acquisition agreement

-

Celgene

acquired rights for $640mm ($340mm upfront)

Thymoglobulin

–

2008 WW sales $180mm

7

Corporate Update: Roll-up Strategy

Rationale

•

Many attractive undervalued and under-resourced late-stage assets

or technology platforms

•

Several large institutional funds preliminarily interested in putting

money to work behind CTI’s

proven acquisition track record

In preliminary discussions with two funds interested in

committing up to $75mm each at any time over two years

for targeted acquisitions or licensing transactions

Strategy/Focus:

•

Secure dedicated funding source at attractive terms

•

Next generation chemo-immunotherapy product

•

Novel targeted therapy in Phase III for leukemia

•

Supportive care product for chemotherapy-induced neuropathy

8

Corporate Update: Summary

Continued progress advancing existing pipeline products

toward commercialization

Upcoming potential key milestones expected over next 12

months

•

FDA decision expected on appeal

•

PIX 306 initiation

•

Targeting execution of 1 or more acquisition candidates

•

Expected

interim

Phase

III

Opaxio

™

ovarian

cancer

results

If obtained, committed funding could relieve debt overhead

and “going concern”

concerns

2011 “Year of the Rabbit”

–

persistence and good fortune!